Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Siefker‐Radtke, Arlene O.; Necchi, Andrea; Park, Se Hoon; García-Donás, Jesús; Huddart, Robert; Burgess, Earle F; Fleming, Mark T.; Kalebasty, Arash Rezazadeh; Mellado, Begoña; Варламов, Сергей; Joshi, Monika; Durán, Ignacio; Tagawa, Scott T.; Zakharia, Yousef; Akapame, Sydney; Santiago-Walker, Ademi; Monga, Manish; O’Hagan, Anne; Loriot, Yohann

doi:10.1016/s1470-2045(21)00660-4

Cited by 87 publications

(51 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a phase 2 study by Loriot et al, erdafitinib was used to treat highgrade/metastatic BCa with FGFR alterations after chemotherapy or neoadjuvant therapy, and the ORR was nearly 40% (CRR of 3% and partial response rate of 37%) [161]. A recent long-term follow-up study by Radtke et al also confirmed the therapeutic activity of erdafitinib with an ORR of 40% (95% CI: 30-49%) and adverse events of stomatitis and hyponatremia of 14% and 11%, respectively [162].…”

Section: Oncolytic Virusesmentioning

confidence: 90%

Advances in Diagnosis and Therapy for Bladder Cancer

2022

Cancers

View full text Add to dashboard Cite

Bladder cancer (BCa) is one of the most common and expensive urinary system malignancies for its high recurrence and progression rate. In recent years, immense amounts of studies have been carried out to bring a more comprehensive cognition and numerous promising clinic approaches for BCa therapy. The development of innovative enhanced cystoscopy techniques (optical techniques, imaging systems) and tumor biomarkers-based non-invasive urine screening (DNA methylation-based urine test) would dramatically improve the accuracy of tumor detection, reducing the risk of recurrence and progression of BCa. Moreover, intravesical instillation and systemic therapeutic strategies (cocktail therapy, immunotherapy, vaccine therapy, targeted therapy) also provide plentiful measures to break the predicament of BCa. Several exploratory clinical studies, including novel surgical approaches, pharmaceutical compositions, and bladder preservation techniques, emerged continually, which are supposed to be promising candidates for BCa clinical treatment. Here, recent advances and prospects of diagnosis, intravesical or systemic treatment, and novel drug delivery systems for BCa therapy are reviewed in this paper.

show abstract

Section: Oncolytic Virusesmentioning

confidence: 90%

Advances in Diagnosis and Therapy for Bladder Cancer

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Erdafitinib is an orally bioavailable selective and potent inhibitor of FGFR1–4 [ 17 ]. Erdafitinib was evaluated in an open-label, single-arm, phase II trial of 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma with FGFR2 or 3 mutations or fusions who had progressed on prior platinum-based chemotherapy [ 51 , 52 ]. Notably, the dose of erdafitinib was guided by off-cancer on-target induction of hyperphosphatemia by inhibition of FGFR1.…”

Section: Fgfrsmentioning

confidence: 99%

“…The primary endpoint of objective response rate (ORR) was achieved in 40% of patients (3% complete, 37% partial). The median progression-free survival (PFS) was 5.5 months, and the median overall survival (OS) was 11.3 months after a median follow-up of 24 months [ 52 ]. The response rate was not affected by visceral metastasis.…”

Section: Fgfrsmentioning

confidence: 99%

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer

Thomas

Sonpavde

2022

Cancers

View full text Add to dashboard Cite

Despite the introduction of immune checkpoint inhibitors and antibody–drug conjugates to the management of advanced urothelial carcinoma, the disease is generally incurable. The increasing incorporation of next-generation sequencing of tumor tissue into the characterization of bladder cancer has led to a better understanding of the somatic genetic aberrations potentially involved in its pathogenesis. Genetic alterations have been observed in kinases, such as FGFRs, ErbBs, PI3K/Akt/mTOR, and Ras-MAPK, and genetic alterations in critical cellular processes, such as chromatin remodeling, cell cycle regulation, and DNA damage repair. However, activating mutations or fusions of FGFR2 and FGFR3 remains the only validated therapeutically actionable alteration, with erdafitinib as the only targeted agent currently approved for this group. Bladder cancer is characterized by genomic heterogeneity and a high tumor mutation burden. This review highlights the potential relevance of aberrations and discusses the current status of targeted therapies directed at them.

show abstract

“…It also reduces the activity of 1 alpha-hydroxylase and the production of calcitriol, thus decreasing the absorption of intestinal phosphate. FGF23 inhibitors are a new class of drugs approved for locally advanced or metastatic urothelial carcinoma and cholangiocarcinoma with genetic alterations [19][20][21][22][23]. FGFR inhibitors decrease the FGF23 enzyme activity and induce a decrease in phosphate renal excretion.…”

Section: Hyperphosphatemiamentioning

confidence: 99%

Electrolytes disturbances in cancer patients

Turcotte

Achi

Mamlouk

et al. 2022

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

Purpose of reviewHypernatremia, hyperphosphatemia, hypocalcaemia, hyperkalaemia and hypermagnesemia are electrolytes disturbances that can arise in cancer patients in relation to unique causes that are related to the cancer itself or its treatment and can lead to delay or interruption of cancer therapy. This article summarizes these main causes, the proposed pathophysiology and the recommended management for these disturbances. Recent findingsThere have been many cancer drugs approved in the field of oncology over the past several years and a subset of these drugs have been associated with electrolytes disturbances. This includes, for example, immune checkpoint inhibitor related hyperkalemia, fibroblast growth factor 23 inhibitor associated hyperphosphatemia and epidermal growth factor receptor inhibitor associated hypomagnesemia and hypocalcaemia. SummaryThis article provides an updated review of certain electrolytes disturbance in cancer patients and allows clinicians to have a greater awareness and knowledge of these electrolyte abnormalities in efforts to early recognition and timely management.

show abstract

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Cited by 87 publications

References 25 publications

Advances in Diagnosis and Therapy for Bladder Cancer

Advances in Diagnosis and Therapy for Bladder Cancer

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer

Electrolytes disturbances in cancer patients

Contact Info

Product

Resources

About